White Paper

One size doesn’t fit all: A new age in healthcare

Download the white paper

In 2016, the US annual cost of drug-related morbidity and mortality resulting from non-optimized medication was estimated to be $528.4 billion, demonstrating the devastating effect treatment mismanagement can have on both society and the economy.

In this white paper, we have collaborated with industry leaders to report on the future of digitization and personalized medicine, exploring health and economic opportunities within the sector. The report collates expert insights and market research across digital health technologies, health equity and financial projections, including comments from key opinion leaders within healthcare, academia and business. Download the full white paper, for free, by clicking the link on top of the page.

Dr Paul Goldsmith

MA, Bm, BCh, MRCP, PhD

Chief Medical & Innovation Officer, Co-Founder & President

Hakim Yadi


Chief Executive Officer & Co-Founder

Watch our CEO and Co-Founder delve into the future of care


Drug-related morbidity and mortality resulting from non-optimized medication costs the US $528.4 billion per year—equating to 16% of US healthcare expenditures.

Watanabe et al.

Over a recent five-year period in the US, nearly 8 out of every ten drugs approved by the FDA had only one dosing regimen.

Schuck, RN, et al.

Historically, we’ve studied and prescribed medications for their average effects in a population, rather than how they perform for each individual in daily life. With new technologies, we’re likely to realize the benefits of personal optimization in dosing.

David van Sickle
Co-Founder and Ex CEO of Propeller Health

The strategic and innovative use of digital and cutting-edge information and communication technologies will be an essential enabling factor towards ensuring that 1 billion more people benefit from universal health coverage, that 1 billion more people are better protected from health emergencies, and that 1 billion more people enjoy better health and well-being.

World Health Organization

While over 80% of providers believe there are advantages to integrating DTx in patient care, adoption of remote monitoring and patient engagement tools remains below 35%.

Blumberg Capital
AMA 2020

Digital therapeutics need to coexist in supporting drug therapy—they must be additive or synergistic.

Professor Shafi Ahmed
MD, The Royal London Hospital